DexCom (DXCM) Rating Lowered to Buy at BidaskClub

DexCom (NASDAQ:DXCM) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday, December 22nd.

Other analysts have also issued research reports about the company. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (down previously from $85.00) on shares of DexCom in a research note on Thursday, September 28th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price target (down previously from $90.00) on shares of DexCom in a research note on Thursday, September 28th. Northland Securities lowered DexCom from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $85.00 to $60.00 in a research note on Thursday, September 28th. JPMorgan Chase & Co. lowered DexCom from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $93.00 to $71.00 in a research report on Thursday, September 28th. Finally, Citigroup lowered DexCom from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 28th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. DexCom has an average rating of “Buy” and an average price target of $71.15.

Shares of DexCom (DXCM) traded down $1.47 during midday trading on Friday, reaching $56.75. 1,222,197 shares of the company’s stock were exchanged, compared to its average volume of 1,462,191. The company has a market capitalization of $4,931.75, a PE ratio of -99.56 and a beta of 0.31. DexCom has a twelve month low of $42.62 and a twelve month high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

In related news, CEO Kevin R. Sayer sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the completion of the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,140 shares of company stock worth $2,158,576. Insiders own 1.70% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in DXCM. JPMorgan Chase & Co. increased its stake in DexCom by 143.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock worth $107,170,000 after acquiring an additional 7,738,678 shares during the last quarter. Janus Henderson Group PLC increased its stake in DexCom by 101,699.8% in the 2nd quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after acquiring an additional 6,822,023 shares during the last quarter. Winslow Capital Management LLC bought a new stake in DexCom in the 2nd quarter worth approximately $117,451,000. Brown Advisory Inc. increased its stake in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after acquiring an additional 1,515,134 shares during the last quarter. Finally, FMR LLC increased its stake in DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after acquiring an additional 978,898 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/14/bidaskclub-downgrades-dexcom-dxcm-to-buy.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply